Key stats
About Tema Neuroscience and Mental Health ETF
Expense ratio
0.75%
Home page
Inception date
Jan 22, 2024
MNTL seeks long-term capital growth by targeting 15 to 100 pure-play companies contributing to neuroscience and mental health. This includes firms involved in pharmaceuticals, emerging biotech, medical devices, and healthcare services. The philosophy centers on identifying growth opportunities within the thematic universe. It uses a two-fold strategy that includes both top-down fundamental sector research and quantitative tools, as well as bottom-up security analysis considering valuation multiples, fundamental metrics, and a detailed research profile of each company. As part of the strategy, ESG considerations are integrated to optimize profits and manage potential risks. Overall, the fund utilizes a comprehensive research and analysis approach that combines internal research, company disclosures, and publicly available sources to assess eligibility. While holdings may include global stocks, a significant portion is expected to be directed toward the US and Europe. The fund may engage in lending transactions.
Classification
What's in the fund
Exposure type
Health Technology
Stock breakdown by region